<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271124</url>
  </required_header>
  <id_info>
    <org_study_id>Effect of exercise training</org_study_id>
    <nct_id>NCT04271124</nct_id>
  </id_info>
  <brief_title>COPD and Inflammatory Mediators</brief_title>
  <official_title>Comparison of Exercise Training</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty of Medicine, Sousse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty of Medicine, Sousse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is
      predicted to be the third leading cause of death by 2020.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD is a common, preventable treatable disease that is characterized by an airflow
      limitation which is not fully reversible.Not only the long-term exposition to noxious
      particles and gases contributes to the development of COPD, but also many others factors such
      as genetics and cigarette smoking. Cigarettes are harmful and contribute to different extra
      pulmonary disorders. Although COPD affects lungs some extrapulmonary manifestations are
      prescribed such as muscle dysfunction, abnormal respiratory muscles and systemic
      inflammation. Indeed, the systemic inflammation[6, 8] is considered as a key process in the
      pathogenesis of COPD. It involves different cells and molecules; high levels of circulating
      of white blood cells, increased plasma c-reactive proteins (CRP), interleukin 6 (Il6) have
      been reported in.those patients.Likewise, systemic inflammation could worsen the
      comorbidities (cardiovascular, osteoporosis..) and may lead to the exercise limitation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Interleukins concentrations</measure>
    <time_frame>Before the training, 2 months</time_frame>
    <description>ELISA assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6Minutes Walk test</measure>
    <time_frame>Before the training, 2 months</time_frame>
    <description>patients performed the test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>PR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PR+ET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exercise training</intervention_name>
    <description>The patients are allocated to PR+ET group or PR Each group receive an exercise training</description>
    <arm_group_label>PR</arm_group_label>
    <arm_group_label>PR+ET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD diagnosed by pulmonary function testing

          -  Clinically stable

          -  Abscence of other obstructive diseases

          -  Signed written consent

        Exclusion Criteria:

          -  Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions

          -  cardiovascular diseases.

          -  Contre-indications to physical therapy

          -  Acute exacerbations a month before the intervention
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yassine Trabelsi, professor</last_name>
    <role>Study Director</role>
    <affiliation>Laboratoire de recherche:Physiologie de l'Exercice et Physiopathologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amal Acheche, PhD</last_name>
    <phone>00216 55028619</phone>
    <email>acheche_amal@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yassine Trabelsi, professor</last_name>
    <phone>00216 20 202 963</phone>
    <email>trabelsiyassine@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratoire de Recherche : Physiologie de l'Exercice et Physiopathologie</name>
      <address>
        <city>Sousse</city>
        <zip>4002</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amal Acheche, phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty of Medicine, Sousse</investigator_affiliation>
    <investigator_full_name>Acheche Amal</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

